Ken Griffin Lantern Pharma Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$3.42 - $4.83 $10,260 - $14,490	-3,000 Reduced 7.01%	39,800 $146,000
Q2 2024 Aug 14, 2024	BUY	$3.91 - $9.51 $89,539 - $217,779	22,900 Added 115.08%	42,800 $199,000
Q1 2024 May 15, 2024	BUY	$3.73 - $10.65 $73,481 - $209,805	19,700 Added 9850.0%	19,900 $175,000
Q4 2023 Feb 14, 2024	SELL	$2.48 - $4.39 $4,960 - $8,780	-2,000 Reduced 90.91%	200 $0
Q3 2023 Nov 14, 2023	BUY	$3.41 - $5.51 $6,820 - $11,020	2,000 Added 1000.0%	2,200 $7,000
Q2 2023 Aug 14, 2023	SELL	$4.56 - $6.02 $33,288 - $43,946	-7,300 Reduced 97.33%	200 $1,000
Q1 2023 May 15, 2023	BUY	$4.3 - $6.2 $3,010 - $4,340	700 Added 10.29%	7,500 $36,000
Q4 2022 Feb 14, 2023	SELL	$4.19 - $6.04 $18,855 - $27,180	-4,500 Reduced 39.82%	6,800 $41,000
Q3 2022 Nov 14, 2022	BUY	$4.59 - $6.5 $51,867 - $73,450	11,300 New	11,300 $54,000

1.29M

39.8K

6.1K

Ticker LTRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 10,830,900
Market Cap $38.3M
Description
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-30...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.